Antigen-specific active immunotherapy for ovarian cancer

NICE Quality and Productivity Case Studies
Queen's University Belfast
Publication date:
17 November 2014


NICE summary of review conclusions

Antigen-specific active immunotherapy for ovarian cancer is not supported by sufficient good quality evidence. Consideration could be given to using it only within the context of a research or audit project.

Reducing or stopping antigen-specific active immunotherapy for ovarian cancer is likely to improve the quality of patient care by reducing exposure to unproven therapies and result in productivity savings.

The Implications for practice section of the Cochrane review stated:

At this point in time, there is no evidence of effective immunotherapy for ovarian cancer. Although promising immunological responses have been observed for most strategies evaluated, these do not coincide with clinical benefits for ovarian cancer patients. Furthermore, there are currently no immunological surrogate markers that correlate with clinical outcomes. Until evidence of true clinical effectiveness is available, immunotherapy should therefore not be offered as an alternative to standard therapy for primary or recurrent ovarian cancer.